Introduction. Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Slides:

Advertisements

Similar presentations

1 Workshop on the immunological basis of vaccine efficacy Vaccine and Infectious Disease Institute December 14, 2009 Ira M. Longini, Jr. Center for Statistical.

Advertisements

Strategies for Targeting and Eradicating the HIV Reservoir

North American Neuromodulation Society Meeting 2012 Harnessing the Inflammatory Reflex: Using Neuromodulation as a Novel Approach to Treat Chronic Inflammatory.

Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.

Introduction to Pathology And its rule in the diagnostic process Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University.

Q1 Which of the following descriptions about HIV and TB interaction is right ? Which of the following descriptions about HIV and TB interaction is right.

Introduction to Pathology And its rule in the diagnostic process Dr: Wael H.Mansy, MD Assistant Professor College of Pharmacy King Saud University.

The Evaluate Trial. Rationale and Design of the Eplerenone Combination Versus conventional Agents to Lower blood pressure on Urinary Antialbuminuric Treatment.

Phase 3 Treatment-Naïve and Treatment-Experienced

Effects of Switching ZDV-3TC to TDF-FTC or ABC-3TC SWAP

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Talking to Patients About HCV Treatment

IL-12 and IL-23.

Chronic Hepatitis C Virus Infection

The Immune System. The Immune System Adaptive Immune Response.

Starting Strong: Initial Evaluation of the Patient With HCV

Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.

Introduction/Background

Progression After Cancer Immunotherapy in Advanced NSCLC

HIV Management: An Update on the Latest EACS Guidelines

Progressive Fibrosing Interstitial Lung Diseases – Addressing the Challenges Concept of Progressive Fibrosing ILDs With Examples.

The ABCs of Nitric Oxide in the Skin

? Neutralizing Antibodies: Research pathways in 2013 and beyond

More Than Treatment.

Chronic Idiopathic Urticaria

Metabolically Healthy Patients With Obesity

Evaluation of the Patient With HCV Infection

Assessing Disease Progression in MS Treatment

Assessing the State of Statin Therapy

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Precision Management of RA and Comorbidities

Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.

HCV Protease Inhibitors in Clinical Practice

Treating mRCC After Initial Antiangiogenic Therapy:

Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.

Is RA Treatment Addressing the Real Needs of Patients?

Personalizing Statin Therapy in Patients With HIV

Gene Therapy: Past, Present, and Future

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Statins and HIV:.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

Biotherapeutics.

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Treating CD30-Expressing Cutaneous T-Cell Lymphoma

Expert Perspectives on the Clinical Use of Immune Reconstitution vs Escalation Therapy for MS.

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

Advances in Severe Asthma Management

IBD Increases Risk for Vaccine-Preventable Diseases

Hepatitis C: After the Diagnosis

Managing Age-Related Clinical Issues in Hemophilia

HCV Protease Inhibitors in Clinical Practice

Severe Asthma and Comorbidities

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

What Does the Future Hold and What Will It Mean for Patients?

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Pathophysiologic Targets of Allergic Asthma

Introduction. Welcome to this program, titled De-Escalating Therapy in Epilepsy: A Return to Monotherapy.

Uptitration of Medications in HF: Start Low but Aim High and Stay High

Hypothetical model of fatigue in a chronic immunological condition.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

MS, Age, and Immune Function

Updates in Progressive MS

My PAH Patient.

Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure

Presentation transcript:

Looking Beyond HIV Infection: CCR5 Blockade as an Immunomodulatory Concept

Introduction

Inflammation-Associated Disease in HIV-Infected Adults

SMART Trial*: Markers of Inflammation and Coagulation Associated With Increased Mortality

Multifactorial Mechanisms Driving Systemic Immune Activation in Chronic HIV Infection

Therapeutic Agents Evaluated in HIV for Their Effect on Immune Activation

Mediators of Inflammation: CCR5

Clinical Trials Evaluating CCR5 Antagonism in Non-HIV-Infected Patients

CCR5 Antagonism in the Treatment of RA

CCR5 Blockade in the Prevention of GVHD

CCL5/CCR5 Interactions in Cancer

Maraviroc: CCR5 Antagonist for the Treatment of HIV

CCR5 Blockade for Neuroinflammatory Diseases

Effects of Maraviroc Treatment on CIMT in HIV-1/HCV Coinfected Patients

CADIRIS Study: CCR5 Antagonism Failed to Decrease IRIS in HIV Infection

Maraviroc Intensification of cART in Patients With Suboptimal Immunologic Recovery

HIV: An Inflammatory Disease

Conclusions

Abbreviations

Abbreviations (cont)